Last reviewed · How we verify
Disitamab Vedotin Plus Cadonilimab
At a glance
| Generic name | Disitamab Vedotin Plus Cadonilimab |
|---|---|
| Sponsor | Zhejiang Cancer Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients (PHASE1, PHASE2)
- RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer (PHASE2)
- Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma (PHASE2)
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy (PHASE2, PHASE3)
- A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab Vedotin Plus Cadonilimab CI brief — competitive landscape report
- Disitamab Vedotin Plus Cadonilimab updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI